Vectibix
Vectibix ingredients
| Active ingredient | Strength |
|---|---|
| Panitumumab | 100 mg/5mL, 400 mg/20mL |
What Vectibix is used for
The FDA lists the approved uses on the official label (below). In the EU, panitumumab is approved as Vectibix for:
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): in first-line in combination with Folfox or Folfiri. in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Vectibix
- Generic name
- Panitumumab
- Made by
- Amgen, Inc
- Forms
- Solution
- Given
- Intravenous
- Drug class
- Epidermal Growth Factor Receptor Antagonist
- FDA approval
- Biologic licence (BLA) BLA125147
- On the US market since
- 2006
Official information
- Vectibix prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Panitumumab)
In India
- Panitumumab: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vectibix?
Vectibix (Panitumumab) is a cancer medicine made by Amgen, Inc, approved by the US FDA.
What are the ingredients of Vectibix?
Vectibix contains Panitumumab (100 mg/5mL, 400 mg/20mL).
Is Vectibix approved in Europe?
The same active substance is approved in the EU as Vectibix.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA